­

About admin

This author has not yet filled in any details.
So far admin has created 98 blog entries.

OncBioMune Announces Former Puma Biotechnology Executive and Genentech Veteran Brian Barnett, M.D., as Chief Executive Officer

BATON ROUGE, La., Jan. 09, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical [...]

Site Visit Planned for December 19, 2018 to Initiate Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer

BATON ROUGE, La., Dec. 07, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

2018 Global Summit on Genitourinary Malignancies Presentation

2018 Global Summit on Genitourinary Malignancies

OncBioMune Phase 2 Clinical Trial to Begin Enrollment; Company Announces Other Development and Corporate Milestones

BATON ROUGE, La., Oct. 31, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune CEO Dr. Jonathan Head Speaking at 2018 Global Summit on Genitourinary Malignancies

BATON ROUGE, La., Oct. 31, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Late Stage Prostate Cancer

BATON ROUGE, La., Oct. 16, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune Initiates Phase 2 Clinical Trial of Novel Vaccine as Front-Line Treatment for Prostate Cancer

BATON ROUGE, La., Sept. 27, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune’s Phase 2 Clinical Trial of ProscaVax for Early-Stage Prostate Cancer is Now Included on ClinicalTrials.gov

BATON ROUGE, La., July 09, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune to Commence Phase 2 Trial of ProscaVax for Early Stage Prostate Cancer Patients

BATON ROUGE, La., June 20, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune Returns Protocol to Scientific Review Committee Overseeing Phase 2 Prostate Cancer Clinical Trial

BATON ROUGE, La., March 28, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]